Valneva SE

Valneva SE is a specialty vaccine company dedicated to developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with unmet medical needs. The company's mission is to advance vaccines for better lives by focusing on providing first-, best-, or only-in-class vaccine solutions. Headquartered with its registered office in Saint-Herblain, France, Valneva also maintains an operational headquarters in Vienna, Austria, where its R&D activities are centralized. [1, 2, 7, 8, 11, 15, 16, 17, 19, 25, 28, 31, 32]

Valneva's commercial portfolio includes three proprietary travel vaccines: IXCHIQ, the world's first single-dose chikungunya vaccine; Ixiaro/JESPECT for Japanese encephalitis; and Dukoral for cholera and enterotoxigenic Escherichia coli (ETEC) diarrhea. [1, 9, 10, 16, 17] These vaccines target market segments such as travelers, military personnel, and individuals in endemic regions. [9, 17] The company also has a robust pipeline of vaccine candidates, including VLA15 for Lyme disease (partnered with Pfizer), as well as candidates against Shigella and Zika. [7, 9, 12, 16, 17, 18, 31, 32]

Under the leadership of CEO Thomas Lingelbach, Valneva recently completed an €84 million reserved offering in April 2026 to bolster its R&D efforts and strengthen its balance sheet. [3, 4, 5, 8, 12, 14, 15, 16, 18, 22] In March 2026, Valneva and Pfizer announced strong efficacy results from the Phase 3 VALOR trial for their Lyme disease vaccine candidate, VLA15, with Pfizer intending to pursue regulatory approval despite the trial missing a primary statistical endpoint due to fewer-than-anticipated cases. [7, 12, 14, 18, 32] The company is also undergoing a restructuring plan, including workforce reduction, to optimize expenses and concentrate resources on its core business and strategic projects. [8]